FDA ANDA Status and Aiping Pharmaceutical's Market Exit

Aiping Pharmaceutical Inc.'s ANDA 078499 for Topiramate generic, with the latest labeling supplement application (SUPPL-9), received FDA approval on June 15, 2026. This product, available in 25mg, 50mg, 100mg, and 200mg oral tablets, has been discontinued. Since its initial approval in January 2010, it has undergone a total of seven supplement applications, primarily focused on maintaining updated safety labeling. This represents a typical case of a small CDMO company, operating with facilities in New York, Long Island, and Zhongshan, China, failing to achieve profitability in an oversupplied market.

The Highly Competitive Landscape of the Topiramate Generic Market

Topiramate, marketed as Topamax by Janssen Pharmaceuticals (a Johnson & Johnson subsidiary), initially received FDA approval (NDA 020505) for epilepsy in December 1996 and subsequently for migraine prophylaxis in 2004, becoming a blockbuster anti-epileptic drug. It exhibits a multi-faceted mechanism of action, including GABA(A) receptor enhancement, sodium channel blockade, and carbonic anhydrase inhibition. Following the expiration of the core patent in September 2008, over 24 companies, including Teva (TEVA), Viatris/Mylan (VTRS), Sun Pharma, Apotex, Zydus, Aurobindo, Cipla, Dr. Reddy's, and Lupin, entered the market, leading to intense price competition. Mylan secured 180-day market exclusivity in 2006, effectively eliminating barriers to market entry.

Market Size and Growth Prospects

The global Topiramate market grew from USD 1.34 billion in 2025 to USD 1.43 billion in 2026 and is projected to reach USD 2.38 billion by 2032, with a CAGR of 8.52%. The market is driven by the management of epilepsy and the prevention of migraines, with both adult and pediatric populations as target demographics. However, immediate-release (IR) tablets have become highly commoditized, resulting in extremely thin margins. Only differentiated formulations, such as the extended-release formulations Trokendi XR (Supernus Pharmaceuticals) and Qudexy XR, and the oral solution Eprontia (Azurity Pharmaceuticals), maintain premium pricing.

CGRP Inhibitors Eroding the Migraine Market Share of Topiramate

In the area of migraine prevention, CGRP (calcitonin gene-related peptide) inhibitors are rapidly eroding Topiramate's market share. Novel drugs with specific mechanisms of action, such as Aimovig (erenumab, Amgen/Novartis), Ajovy (fremanezumab, Teva), Emgality (galcanezumab, Eli Lilly), and Qulipta (atogepant, AbbVie), have gained prominence, with CGRP monoclonal antibody segments accounting for 56.68% of migraine treatment market revenue in 2024. While Topiramate remains a low-cost, first-line prophylactic agent, it is undergoing a structural shift where its prescription priority is being relegated to a secondary position compared to newer drugs.